Prostate cancer has been known to run in families for about 40 years and epidemiological studies have demonstrated an increased risk to close relatives of cases. This risk rises markedly when the closeness and number of cases in a cluster increases. There has been considerable debate about the genetic model, in particular whether there is a commoner lower penetrance (moderately increased risk of the disease due to the gene(s)) in addition to contribution from high risk genes. For the ®rst time, molecular results are starting to emerge, indicating the location of high risk genes. These have shown that there is evidence for more than one site of a high risk, gene two sites on chromosome 1 and one on chromosome X. These do not account for all clusters of prostate cancer cases and further genes remain to be discovered. This article also outlines the contribution of the numerous collaborators in the British Prostate Group to the UK Familial Prostate Cancer Study.
Introduction
Prostate cancer is a signi®cant public health problem, there are about 14 000 cases per year in England and Wales, and 8742 deaths. 1, 2 In the USA, it is the most common malignancy and the second most common cause of cancer deaths, with 209 900 cases and 41 480 deaths in 1997 3 ; a component of this cancer burden is the policy of screening in the USA, which will detect histological cancer which may not contribute to mortality. However, the incidence in Europe is increasing by 10 ± 20% every 5 y, even when screen-detected cancers are disregarded. 4 Prostate cancer has traditionally been considered a cancer of elderly men; however, 13% of cases occur in men in their pre-retirement years in the UK, equivalent, for example, to just over the total number of testicular cancers per year. The characterisation of genetic alterations which are in the germline and predispose to disease will enable the identi®cation of individuals at increased risk, and may provide an insight into the pathogenesis of sporadic disease.
Evidence for genetic predisposition to prostate cancer
The ®rst piece of evidence that predisposition to prostate cancer has a genetic component is the presence of familial clustering. The best examples are the large Utah kindreds, some containing over 20 cases. 5 Many other groups have collected familial clusters and it is interesting to note that these are, with few exceptions, small clusters of usually three or four cases. Relatively few families with eight or more cases exist. Large clusters, such as those seen in familial breast cancer studies, are not common in prostate cancer families, and a possible reason for this is further discussed in the section relating to the genetic model.
There have been two types of case-control study: one compared the number of prostate cancer cases in relatives of cases vs controls, and the other compared the percentage of cases vs controls with a positive family history of prostate cancer. These studies 6 ± 18 are summarised in Table 1 . The relative risk of prostate cancer in ®rst-degree relatives of cases range from 1.76 ± 11.00 in the ®rst study type, and from 0.64 ± 7.50 in the second. Only one study 13 has a reduced relative risk in relatives and it only consists of 39 cases. There have been two cohort studies, the ®rst American 19 and the second Swedish 20 ; these showed relative risks of prostate cancer of 2.20 (95% CI 2.0 ± 2.4) and 1.70 (95% CI 1.51 ± 1.90), respectively.
Evidence that the increased risk to relatives in epidemiological studies has a genetic component
The increase in the size of the relative risks from the casecontrol studies as clustering becomes more dramatic suggests a genetic effect. The relative risks of prostate cancer due to other factors, such as age at ®rst marriage, are all about 1.5, which is the level of risk from hormonal factors in breast cancer aetiology. All but one of the relative risk ®gures in the familial studies are higher than this, and all but three are higher than 2.0. The best evidence that there is a genetic effect is that the relative risk markedly increases as the age of the proband decreases (Table 2) , as the closeness and number of affected members in the family increases (Tables 3 and  4) , or when both factors are considered together (Table 5) . A change in relative risk of this magnitude as clustering increases cannot be explained solely by a common environmental effect in each cluster.
The genetic model
There is considerable debate at present about the genetic model for prostate cancer predisposition. Carter et al 21 performed a segregation analysis using 691 nuclear families. The results suggest that familial prostate cancer is due to a rare, highly penetrant, dominant gene or genes, the ®rst of which has been named HPC1. The gene frequency is predicted to be 0.003 and to cause 43% of cases by age 55 y and 9% by age 80 y. The penetrance in gene carriers would be 88% by age 85 y. However, the probands were highly selected for young age at onset (`65 y). A subsequent analysis of a population-based study of 2857 nuclear families in Sweden supports a high risk dominant allele model, but with a higher gene frequency of 0.0167 and a lower penetrance of 63%. 22 Until recently, all familial cancer was thought to be caused by tumour-suppressor genes. Carcinogenesis in such cases arises following the Knudson two-hit hypothesis, where the ®rst hit is inherited, and loss of the remaining normal or wild-type allele results in tumour development. 23 However, it is now thought that a least one familial syndrome (MEN2) is caused by mutations in a dominant oncogene, as the normal allele is not lost at the predisposition locus in tumours. 24 The mechanism(s) of action of the prostate cancer predisposition gene is unknown.
Narod et al 25 have suggested that because the risk of prostate cancer is higher in brothers than in fathers of cases, a recessive genetic model should be used. However, this could be explained by a screening effect leading to over-diagnosis in brothers of cases. Monroe et al 26 also suggest a recessive or X-linked model. There is now some evidence for this from linkage studies (see note in proof).
The observation that the clusters are smaller than are observed in other common cancers, for example, breast and colon cancer, could be explained either by a lower recall of family history in males or by the model that prostate cancer predisposition is due to a commoner, lower penetrance gene than the model predicted by Carter et al. 21 Gro È nberg et al 22 provided some evidence that this is so. If a commoner, lower penetrance gene or genes are present, more men would be gene carriers, and each would be at a lower risk of prostate cancer than predicted by the model of Carter et al. 21 However, the genetic component would contribute to more prostate cancer cases overall. Such gene(s) would be more dif®cult to ®nd, as in the larger clusters seen in the Utah families, several genes could be present within one cluster, and linkage studies to investigate evidence for the presence of linkage of one gene within one cluster would actually fail to show evidence for linkage to one locus alone. An approach to overcome this problem is to study smaller clusters; those identi®ed either as isolated small clusters or as individual small clusters within larger kindreds such as those from Utah. If a sibling pair approach is used, assuming two genes of equal effect (with a relative risk of 4), at least 200 pairs need to be studied. If the gene(s) is a tumour suppressor, the use of tumour sample loss of heterozygosity (LOH) can be incorporated into the linkage analysis and this decreases the required number of affected pairs to about 100 (D. Easton, personal communication). The analysis involves the assessment of the inheritance of genetic areas in common in the two affected individuals to a greater extent than would be expected by chance.
Familial aggregation of prostate cancer with other cancers
Another piece of evidence for a genetic component is the clustering of prostate cancer with other cancers. A higher incidence of prostate cancer among male relatives of patients with breast cancer has been reported. 27 32 Three studies 11, 19, 33 have shown a signi®cant association of prostate cancer with brain tumours, but other studies have not con®rmed this. A study of relatives of patients with soft tissue sarcoma has shown that there is a 1.9-fold increased risk of prostate cancer in these relatives, although this is not statistically signi®cant (95% CI 0.7 ± 5.1). 34 The search for the gene(s) predisposing to familial prostate cancer
The study of familial prostate cancer is complicated by the fact that there may be many sporadic cases in families, as prostate cancer is so common. In addition, screendetected family history may behave differently from symptomatic disease. Men with a positive family history may be more likely to undergo screening, which may detect histologically de®ned disease which would not necessarily progress, and, in theory, this could have a different genetic basis from clinically signi®cant disease.
Several groups have been collecting information on families with prostate cancer and performing linkage analysis (which is the co-inheritance of genetic markers of known chromosomal position with the disease) or direct mutation analysis of candidate genes. The ®rst results of a genome-wide linkage search were published in 1996 by Smith et al 35 who found evidence for linkage on chromosome 1q24-25 with a maximum multipoint LOD score of 5.43 (a LOD score of over 3 is considered to be statistically signi®cant). Interestingly, two of the linked families were African ± American and contributed to over 1.00 of the total LOD score. Subsequently, several other groups have tried to con®rm this ®nding and Cooney et al 36 37 In contrast, McIndoe et al 38 reported negative two-point LOD scores across the region in a series of 49 families, none of which were African ± American. The UK/Canadian/Texan Linkage Consortium 39 had negative evidence for linkage in the region in 136 prostate cancer families; the estimated proportion of families linked to 1q was 4% and there was no evidence for linkage in families with three or fewer cases. In families with four or more cases (a total of 35 families typed), up to 20% of families could have been linked on the heterogeneity analysis (this analysis allows for the fact that a proportion of families but not all may be linked and estimates this proportion). The gene on 1q has not yet been identi®ed. It is possible that it lies distal to the region identi®ed by Smith et al 35 as a recent French study has suggestive evidence for linkage to 1q42. 40 A further analysis by Gro È nberg et al 41 of the families linked to the 1q24 locus from data in the study by Smith et al, 35 has shown that men in potentially linked families have a signi®cantly lower age at diagnosis than men in potentially unlinked families (63.7 vs 65.9 y, P 0.01). Grade 3 and higher stage cancers were more common in potentially linked families. 42 Conversely, hereditary prostate cancer overall has been associated in some reports with lower grade although there were no other clinical or pathological differences. 43 This is at odds with another report comparing pathological features of hereditary prostate cancer and sporadic disease which show no histological difference between the two groups, although only small numbers have been studied. 44 An ideal candidate for a prostate cancer predisposition gene would have been the androgen receptor (AR) gene on Xq, but this is unlikely to be the high risk susceptibility gene, at least in some families, as male/male transmission occurs. 25, 33, 45 In other families, maternal transmission excludes the Y chromosome as a site for the predisposing gene.
Other candidate genes would include BRCA1 and BRCA2, 32, 46 which confer a relative risk of prostate cancer of 3.0 and about 2.6 ± 7.0, respectively (D. Easton, personal communication), and TP53 and RB, which are involved later in prostate cancer pathogenesis. 47, 48 The UK/Canadian/Texan Consortium has analysed the contribution of BRCA1 and BRCA2 to small prostate cancer clusters in a study of 100 clusters. Up to 30% may be linked to BRCA1/2, however the con®dence intervals were wide and included zero. Direct mutation analysis of 38 prostate cancer clusters from the UK Familial Prostate Cancer Study has not revealed any BRCA1 mutations, however 2 germline mutations have been found in BRCA2. 49 The problem with these mutations is that, although they are deletions and would be expected to be cancer-causing and the wild-type copy of BRCA2 is lost in the tumour material; the brother of the case, who was also affected, did not in either instance carry the mutation. The mutation may therefore be either a coincidental ®nding or, more interestingly, might be acting as a modi®er gene in¯uencing the expression of another prostate cancer predisposition gene within the cluster. It is interesting to note that in Icelandic cancer families that carry a BRCA2 mutation, there is variability of expression of the prostate cancer; those families with larger numbers of male breast cancer have a smaller incidence of prostate cancer and vice versa. 46 It is interesting to postulate that BRCA2 may therefore be acting as a modi®er in this population also for prostate cancer risk and this warrants further investigation. Two other candidate genes have recently been cloned, MXI1 on 10q in which mutations have been found in prostate tumours, 50 and a metastasis-suppressor gene, KAI1 at 11p11.2. 51 It is very unlikely that MXI1 is HPC1 from mutation analysis of 38 individuals at increased risk from prostate cancer in clusters from the CRC/BPG UK Familial Prostate Cancer Study. 52 Allele-loss studies or LOH indicate the sites of tumoursuppressor genes as, in the tumour, the wild-type allele is lost, resulting in the tumour-suppressor gene exerting an unopposed effect. Individuals heterozygous for markers in the area of loss, therefore, have their heterozygous state reduced to homozygosity, hence the term LOH. The most favoured candidates for locations of a tumour-suppressor gene in prostate cancer from tumour LOH studies are chromosomes 8p, 10q and 16q, because the highest percentage of loss (30 ± 50% of tumours) is in these regions. 53, 54 In one study of 52 sporadic prostate cancers, the loss at 8p was present in 63% of tumours, 55 and in a metastasis, a homozygous deletion of part of 8p (8p22) has been found. This deletion narrows the area of loss to a 14 cM interval 55 and is strongly suggestive of a tumoursuppressor gene in this region. Studies of these candidate regions for linkage in the large Utah kindreds failed to ®nd any evidence for linkage in these candidate regions. 56 Another study of 20 tumours with early localised disease has also detected a small commonly deleted region on 18q. 57 In 23 tumours from patients with localised prostate cancer, 52% had LOH at 17q and 44% had LOH with a marker intragenic in the breast cancer predisposition gene BRCA1.
58
Mutations of TP53 are the most common genetic changes in many cancer types 59 ; however, in prostate cancer, TP53 mutation is not very common in primary tumours. Mutations of TP53 were seen in 25% of 92 tumours in one study, 47 but all the mutations were seen in metastatic tissue and were a late event. Similar results have been obtained for the retinoblastoma gene 48 and the DNA polymerase b gene, 60 where changes are more common in metastatic disease than in earlier disease.
Chromosomes transfer studies using microcellmediated chromosome transfer have shown that the introduction of chromosomes 8 or 11 suppresses metastatic ability, but not tumorigenicity, in the highly metastatic Dunning rat AT3.1 prostatic cancer cell line. 61, 62 Tumorigenicity of the human prostate cancer cell line DU 145 in nude mice 63 can be suppressed by transfer of a portion of chromosome 12 (12pter-12q13). These would therefore be candidate areas for the sites of prostate tumour-suppressor genes.
If the prostate cancer susceptibility locus is a commoner, lower penetrance gene, are there any candidates?
One of the roles of the AR is to activate the expression of target genes. This activity is in the N-terminal domain that contains expressed trinucleotide repeats. 64, 65 Several studies 66 ± 70 have shown that there is an association between shorter repeats in the most 5
H repeat area (a run of CAG repeats) and prostate cancer, and a smaller repeat size is associated with a higher level of receptor transactivation function. 65 Although AR has been excluded as a site for the highly penetrant dominant prostate cancer susceptibility locus, it is a candidate for a lower penetrance prostate cancer susceptibility gene, and repeat lengths need to be compared in many systematically collected prostate cancer cases vs controls to con®rm the level of risk as many of the individual studies do not reach statistical signi®cance.
The CRC/BPG UK Familial Prostate Cancer Study
The aim of this collaborative study by 112 urologists, geneticists and oncologists in the UK is to ascertain the contribution of genetic predisposition to prostate cancer. The study (funded by the CRC) has been designed to allow several approaches to this problem. Clusters of multiple case families with three or more cases at any age and affected related pairs (usually sibling pairs where one is aged`65 y at diagnosis) are being collected to search for a highly penetrant prostate cancer susceptibility locus; 119 clusters have been identi®ed and are being sampled. A cohort of young cases (275 to date) aged`55 at diagnosis, have had DNA samples taken to ascertain the contribution of HPC1 and other prostate cancer susceptibility loci (once cloned) to young-onset disease. A systematic series of 1000 cases treated at one centre has been interviewed to obtain details on ®rst-degree relatives. This will be used to ascertain the relative risk (RR) of death of cancer in ®rst-degree relatives of prostate cancer cases by`¯agging' mortality records through the Of®ce of Population Censuses and Surveys. It therefore should give the RR of clinically signi®cant prostate cancer which results in mortality. Subjects in this series have also had DNA samples taken in order to search for lower penetrance genes, by comparing the incidence of polymorphisms in candidate genes in cases with geographically matched controls without prostate cancer.
The collaborators in this study are listed at the end of this paper; further collaborators are welcome.
The patients with prostate cancer sought for this study should fall into one of the following groups:
(i) multiple-case prostate cancer families with three or more cases at any age; (ii) affected blood-related pairs where one is`65 y old at diagnosis; (iii) young cases diagnosed at`55 y of age.
If your patient ful®lls one of these eligibility criteria and you wish to collaborate in this study, we would be grateful if you would ask them verbally if they are happy to take part. Participation would involve completing a questionnaire and giving a blood sample. This and the written consent is all obtained by the study research nurse and clinical nurse specialist (Annette Murkin/Audrey Ardern-Jones). All collaborators are part of the co-authorship of all publications arising from this study, as in this article. Dr Eeles 
